- Home
- ALHC vs BLTE Comparison
ALHC vs BLTE Comparison
Compare ALHC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALHC
- BLTE
- Stock Information
- Founded
- ALHC 2013
- BLTE 2018
- Country
- ALHC United States
- BLTE United States
- Employees
- ALHC N/A
- BLTE N/A
- Industry
- ALHC Medical Specialities
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- ALHC Health Care
- BLTE Health Care
- Exchange
- ALHC Nasdaq
- BLTE Nasdaq
- Market Cap
- ALHC 2.1B
- BLTE 2.1B
- IPO Year
- ALHC 2021
- BLTE 2022
- Fundamental
- Price
- ALHC $11.49
- BLTE $82.81
- Analyst Decision
- ALHC Buy
- BLTE Strong Buy
- Analyst Count
- ALHC 9
- BLTE 4
- Target Price
- ALHC $10.63
- BLTE $89.00
- AVG Volume (30 Days)
- ALHC 2.0M
- BLTE 110.7K
- Earning Date
- ALHC 10-29-2024
- BLTE 11-12-2024
- Dividend Yield
- ALHC N/A
- BLTE N/A
- EPS Growth
- ALHC N/A
- BLTE N/A
- EPS
- ALHC N/A
- BLTE N/A
- Revenue
- ALHC $2,467,707,000.00
- BLTE N/A
- Revenue This Year
- ALHC N/A
- BLTE N/A
- Revenue Next Year
- ALHC $29.19
- BLTE N/A
- P/E Ratio
- ALHC N/A
- BLTE N/A
- Revenue Growth
- ALHC 43.47
- BLTE N/A
- 52 Week Low
- ALHC $4.46
- BLTE $31.01
- 52 Week High
- ALHC $14.25
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- ALHC 43.08
- BLTE 73.39
- Support Level
- ALHC $12.76
- BLTE $77.62
- Resistance Level
- ALHC $14.20
- BLTE $86.53
- Average True Range (ATR)
- ALHC 0.75
- BLTE 5.84
- MACD
- ALHC -0.13
- BLTE 0.69
- Stochastic Oscillator
- ALHC 18.68
- BLTE 88.01
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.